Roche Holding AG ranks in an above-average position in its peer group, with a broadly solid profile across the main structural dimensions. Price action is modestly ahead of the structural profile — a mild divergence, not yet a decisive signal.
Profitability Strong, Confidence Under Pressure
52w drawdown -11.0% · 21d vs sector +2.7%
Peer-relative scores, weakest to strongest
Roche Holding AG is a global pharmaceutical and diagnostics company headquartered in Switzerland. The group develops and markets prescription medicines and diagnostic systems, focusing on oncology, immunology, and personalized healthcare.
Top-tier profitability, with a 31.7% ROIC and 30% operating margin, positions Roche among the most efficient players in global healthcare. Market confidence and stability remain under pressure, as shown by a 19% EPS miss in Q4 2025 and a series of analyst downgrades. This gap between strong underlying returns and muted sentiment results in mixed valuation support, rather than clearly reflecting Roche’s strengths.
The internal signals reflect this tension. The Q4 2025 EPS of CHF 8.37 fell short of expectations, indicating earnings volatility that has unsettled investors. Erste Group’s recent downward revision of FY2026 EPS estimates indicates a cautious outlook. A one-year maximum drawdown of -42.3% indicates persistent risk aversion, even as Wolfe Research’s Outperform rating and optimism about pricing and the product pipeline provide a positive signal. These strengths are secondary to the core issue: stabilizing earnings delivery and restoring market trust.
External context complicates the picture. Roche’s Q4 revenue beat (CHF 15.65bn) appears solid but does not translate into consistent bottom-line performance. The regulatory environment is pivotal, given Roche’s reliance on innovative drug approvals—delays or setbacks here can quickly reduce rerating prospects. Meanwhile, global shifts toward personalized medicine and biosimilars shape the competitive landscape, introducing both challenges and strategic complexity that can increase volatility compared to steadier peers.
Compared to sector names like GSK and Zoetis, Roche’s profitability metrics are at the upper end, but its recent earnings volatility and analyst caution are more pronounced than many peers. This pattern is partly driven by factors specific to Roche, such as its innovation-heavy portfolio and regulatory exposure, which make it more sensitive to confidence swings than the broader sector.
A more constructive outlook would require market confidence to stabilize and EPS volatility to moderate. Supporting improvement would include a more predictable regulatory approval cadence and successful new product launches. Until then, Roche appears as a quality leader with valuation support under pressure.
Break down ROG.SW's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.